Fibromyalgia (FM) is a condition characterized by chronic generalized pain throughout the body and an increased pain response to pressure stimuli. Symptoms may also include restless legs, fatigue, sleeplessness, increased sensitivity, depression, and trouble with memory.


The cause of Fibromyalgia is unknown, but both genetic and environmental factors are thought to be involved.

Conventional treatments for Fibromyalgia include medications, lifestyle changes, and Cognitive Behavioral Therapy (CBT).

Stem cell researchers are looking to try and decrease the inflammation associated with Fibromyalgia through the immunosuppressive properties of stem cells and their bioactive components. Currently, stem cell treatment aims to repair nerve damage which may result from this disease.

If you would like to talk with an expert about your specific condition, please fill out the
form below:

  • Wish to explore treating this condition with us?

    Fill out the form below for free information

The most current research regarding stem cells and Fibromyalgia is given below:

Autologous Adipose Stem Cell Therapy for Autonomic Nervous System Dysfunction in Two Young Patients
Mohammed T. Numan, Ankur Kamdar, Jane Young, and Ian. J. Butler

Abstract: Postural orthostatic tachycardia syndrome and neurocardiogenic syncope are clinical manifestations of autonomic nervous system dysfunction (dysautonomia) that can lead to impaired daily functions. We report two young patients presenting with dysautonomia and autoimmune disease who both received autologous adipose stem cells (ASCs) infusions. This report is the first description of ASCs therapy for patients with combined dysautonomia and autoimmune disease. Case 1: A 21-year-old female presented at 12 years of age with escalating severe dysautonomia with weight loss and gastrointestinal symptoms. She had elevated autoantibodies and cytokines and received multiple immune modulation therapies. Her dysautonomia was treated by volume expanders, vasoconstrictors, and beta blockers with mild improvement. She received ASCs about 2 years before this report with dramatic improvement in her dysautonomia and autoimmune symptoms with a 10 kg weight gain. Case 2: A 7-year-old boy presented at 2 years of age with polyarthritis. At 5 years of age, he manifested orthostatic intolerance. He received immune modulatory therapies with mild improvement. He received ASCs and showed marked improvement of his dysautonomia and immune symptoms. Dysautonomia symptoms of these two patients improved significantly after modulation of autoimmune components by ASC therapy. Favorable clinical responses of these two cases warrant further case–control studies.